Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Acarbose in Drug-Naive T2DM
NCT03344341Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Dec 2017; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03344341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344341.